Catalent Reports Mixed Q4 Earnings; FY23 Sales Expectation Lags Consensus

  • Catalent Inc CTLT reported Q4 FY22 sales of $1.31 billion, +10% Y/Y as reported, or 15% in constant currency, slightly missing the consensus of $1.33 billion.
  • Fiscal sales reached $4.83 billion, in line with the management guidance of $4.8 billion - $4.9 billion.
  • Adjusted EPS of $1.19, compared to $1.16 last year, surpassed the consensus of $1.15.
  • Adjusted EBITDA was $384 million, or a margin of 29%, compared to $348 million a year ago.
  • Biologics segment sales increased 14% to $667 million.
  • "Our past fiscal year saw record performance and growth for Catalent, due in part to a series of significant investments in production capacity at drug manufacturing facilities in both North America and Europe over the last several years to help us meet needs across high-growth areas of customer demand," said Alessandro Maselli, President & CEO.
  • Related: Catalent-Repligen Merger 'Seems Unlikely,' This Analyst Says.
  • Softgel and Oral Technologies segment revenues of $350 million were up 22%.
  • The Oral and Specialty Delivery segment's sales were $194 million, up 11%.
  • Clinical Supply Services segment revenues improved by 4% to $104 million.
  • Guidance: For FY23, Catalent expects $4.975-$5.225 billion in revenue compared to the consensus of $5.26 billion.
  • It expects adjusted EBITDA of $1.31-$1.390 billion and adjusted net income of $660-$730 million.
  • Price Action: CTLT shares are down 8.15% at $91.58 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!